Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JAZZ PHARMACEUTICALS PLC

(JAZZ)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
133.29 USD   +0.66%
09/29Goldman Sachs Adjusts Jazz Pharmaceuticals' Price Target to $170 From $148, Maintains Neutral Rating
MT
09/21Goldman Sachs Adjusts Jazz Pharmaceuticals' Price Target to $148 From $192, Maintains Neutral Rating
MT
09/19Avecho Biotechnology Validates Bioavailability of Cannabinoid Product in Canine Study
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
127.28(c) 126.59(c) 128.94(c) 132.42(c) 133.29(c) Last
829 221 539 044 605 477 588 184 843 420 Volume
-0.31% -0.54% +1.86% +2.70% +0.66% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 3 643 M - -
Net income 2022 317 M - -
Net Debt 2022 4 923 M - -
P/E ratio 2022 13,8x
Yield 2022 -
Sales 2023 3 773 M - -
Net income 2023 623 M - -
Net Debt 2023 3 825 M - -
P/E ratio 2023 12,9x
Yield 2023 -
Capitalization 8 355 M 8 355 M -
EV / Sales 2022 3,64x
EV / Sales 2023 3,23x
Nbr of Employees 3 200
Free-Float 97,5%
More Financials
Company
Jazz Pharmaceuticals plc is a biopharmaceutical company. The Company is engaged in developing medicines for people with serious diseases. The Company’s products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, which develops for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy aged seven years of age and older; Xyrem (sodium oxybate) oral... 
Sector
Pharmaceuticals
Calendar
11/08Earnings Release
More about the company
Ratings of Jazz Pharmaceuticals plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about JAZZ PHARMACEUTICALS PLC
09/29Goldman Sachs Adjusts Jazz Pharmaceuticals' Price Target to $170 From $148, Maintains N..
MT
09/21Goldman Sachs Adjusts Jazz Pharmaceuticals' Price Target to $148 From $192, Maintains N..
MT
09/19Avecho Biotechnology Validates Bioavailability of Cannabinoid Product in Canine Study
MT
09/15Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022
PR
09/08Jazz Pharmaceuticals Seeks M&A
CI
09/08Transcript : Jazz Pharmaceuticals plc Presents at 2022 Wells Fargo Healthcare..
CI
09/07Jazz Pharmaceuticals plc Reiterates Revenue Guidance for the Full Year 2022
CI
09/07Transcript : Jazz Pharmaceuticals plc Presents at Citi's 17th Annual BioPharm..
CI
08/31Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
PR
08/30Codiak BioSciences to Cut Workforce by 37%; Explore Potential Partnerships to Extend Ca..
MT
08/22Insider Sell: Jazz Pharmaceuticals
MT
08/18Jazz Pharmaceuticals : Corporate Overview
PU
08/18Sector Update: Health Care Stocks Edge Higher Premarket Thursday
MT
08/18Jazz Pharmaceuticals Initiates Phase 3 Trial of Epidiolex to Treat Children With Epilep..
MT
08/18Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyo..
PR
More news
News in other languages on JAZZ PHARMACEUTICALS PLC
09/08Jazz Pharmaceuticals recherche des fusions et acquisitions
09/07Jazz Pharmaceuticals plc réitère ses prévisions de revenus pour l'ensemble de l'année 2..
08/30Codiak BioSciences va réduire ses effectifs de 37% ; explorer des partenariats potentie..
08/22Vente d'initiés : Jazz Pharmaceuticals
08/18Mise à jour sectorielle : Les actions du secteur de la santé son..
More news
Analyst Recommendations on JAZZ PHARMACEUTICALS PLC
More recommendations
ETFs positioned on JAZZ PHARMACEUTICALS PLCETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Rize Medical Cannabis and Life Sciences Acc - USD27.3%-1.59%-World
HANetf The Medical Cannabis and Wellness -...19.96%-0.51%-World
Horizons Marijuana Life Sciences Index ETF - CAD13.11%0.00%North America
PSYK ETF - USD6.89%1.49%-NC
VanEck Vectors Pharmaceutical ETF - USD3.62%-1.14%United_States
More ETFs positioned on JAZZ PHARMACEUTICALS PLC
Chart JAZZ PHARMACEUTICALS PLC
Duration : Period :
Jazz Pharmaceuticals plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAZZ PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 133,29 $
Average target price 198,58 $
Spread / Average Target 49,0%
EPS Revisions
Managers and Directors
Bruce C. Cozadd Chairman & Chief Executive Officer
Daniel N. Swisher President
Renée D. Galá Chief Financial Officer & Executive Vice President
Robert Iannone Chief Medical Officer, EVP-Research & Development
Finbar Larkin Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
JAZZ PHARMACEUTICALS PLC4.62%8 300
JOHNSON & JOHNSON-3.82%432 579
ELI LILLY AND COMPANY21.06%313 567
ROCHE HOLDING AG-15.52%269 089
ABBVIE INC.5.41%252 343
PFIZER, INC.-25.22%247 841